 |
      
|
|
|
|
|
|||||
|
|
August 9, 2004
Neurochem Inc. - No material information that would explain recent trading of common shares. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for
neurological disorders. The Company's pipeline of proprietary, disease-modifying oral products
addresses critical unmet medical needs. Fibrillex™, designated as an orphan drug and as a Fast
Track Product candidate, is also part of a Continuous Marketing Applications Pilot 2 program and
is currently in a Phase II/III clinical trial for the treatment of AA Amyloidosis. Alzhemed™, for
the treatment of Alzheimer's Disease, is in a Phase III clinical trial and Cerebril™, for the
prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase II
clinical trial.
Certain statements contained in this news release, other than statements of fact that are independently
verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as
they are on the current expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include
but are not limited to: the impact of general economic conditions, general conditions in the
pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation as well as other risks included in public filings of Neurochem.
Consequently, actual future results may differ materially from the anticipated results expressed
in the forward-looking statements. The reader should not place undue reliance on the forward-looking
statements included in this news release. These statements speak only as of the date made and
Neurochem is under no obligation and disavows any intention to update or revise such statements as
a result of any event, circumstances or otherwise.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
